No fast way to eighth place for Incyte
Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?
Delays look like the best-case scenario for teplizumab
Picking up the Lilly cast-off might not have been an easy win for Provention after all.
Adcom pours fresh doubts on roxadustat’s US approvability
Just when investors thought they had seen the worst of it, the delayed Fibrogen/Astrazeneca project faces another problem.
Gilead would rather forget filgotinib
The much-heralded Gilead and Galapagos partnership takes a big knock as the US biotech cuts some of its losses with the doomed arthritis project.
